Copay accumulator programs now cover 84% of commercially insured lives, silently stripping manufacturer copay assistance so patients hit a sudden financial cliff mid-year

Pharmaceutical manufacturers offer copay assistance cards for expensive specialty drugs -- a patient taking a biologic for rheumatoid arthritis that costs $6,000/month might pay only $5/month with the card. Historically, these copay card payments counted toward the patient's annual deductible and out-of-pocket maximum, meaning the manufacturer was effectively paying down the patient's cost-sharing obligation. Copay accumulator programs change this: the insurer accepts the manufacturer's copay card payment but does not apply it toward the patient's deductible or out-of-pocket maximum. As of 2025, 84% of commercially insured beneficiaries are enrolled in plans where copay accumulators are available in the plan design. The patient experience is devastating and deliberately opaque. For the first few months of the year, the copay card covers the patient's cost, and everything seems fine. Then the copay card funds are exhausted -- typically by month 4 or 5 -- and the patient suddenly owes the full cost-sharing amount because none of the previous payments counted toward their deductible. A patient on a $6,000/month biologic who thought they were paying $5/month is suddenly billed $2,000 or more in a single month. Many patients cannot pay. They stop taking their medication. For patients with conditions like multiple sclerosis, Crohn's disease, or organ transplant rejection, stopping medication mid-course can cause irreversible disease progression, organ damage, or death. The patient often does not understand why their costs suddenly spiked -- the accumulator program is buried in plan documents that no one reads. This problem persists because copay accumulators are enormously profitable for insurers and PBMs. The manufacturer's copay card pays the insurer for the drug, but the insurer does not credit the patient's deductible, so the insurer collects twice: once from the manufacturer and once from the patient (or avoids paying when the patient abandons treatment). As of March 2025, only 21 states have banned copay accumulators for state-regulated health plans, and these bans do not apply to self-funded employer plans (which cover the majority of commercially insured workers) because of ERISA preemption. The 2025 Notice of Benefit and Payment Parameters rule prohibited copay maximizers but offered no guidance on accumulators, leaving the core problem unaddressed.